Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02910466 · ClinicalTrials.gov registry record · Phase 4
A Study of Extended Use of Recombinant Human Parathyroid Hormone (rhPTH(1-84)) in Hypoparathyroidism
A Phase 4 study of Hypoparathyroidism and Chronic Hypoparathyroidism, sponsored by Shire.
- Completed
- Registry status
- Phase 4
- Development phase
- 39
- Enrollment target
- 1
- Study location
NCT02910466 is a Phase 4 study of Hypoparathyroidism and Chronic Hypoparathyroidism that has completed, run by Shire. The registered enrollment target is 39 participants, below the 196-participant average among 10 other Hypoparathyroidism trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02910466, a Phase 4 study of Hypoparathyroidism and Chronic Hypoparathyroidism, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 39 participants
- Enrollment target
- 1
- Study location
Study Summary
Chronic hypoparathyroidism is a life-long and irreversible disease for which the chronic administration of rhPTH(1-84) is a potential treatment option. The group of participants in the AAAE0544 core study has been taking rhPTH(1-84) for the treatment of hypoparathyroidism for up to 11 years. This study is designed to extend this experience and gain knowledge about how safe and effective rhPTH(1-84) is in participants with hypoparathyroidism over a long-term duration.
Conditions Studied
Interventions
- DRUG rhPTH(1-84)
Study Locations (1)
New York
- Columbia University Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2016-10-27 |
| Est. Completion | 2019-12-20 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02910466
The ClinicalTrials.gov registry entry for NCT02910466 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 196-participant average among 10 other Hypoparathyroidism trials with a reported enrollment target (80% lower). The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hypoparathyroidism appearing as the primary indexed condition, and to 1 intervention - of which rhPTH(1-84) is the first listed.
NCT02910466 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT02910466 about?
NCT02910466 is a clinical study titled "A Study of Extended Use of Recombinant Human Parathyroid Hormone (rhPTH(1-84)) in Hypoparathyroidism". Chronic hypoparathyroidism is a life-long and irreversible disease for which the chronic administration of rhPTH(1-84) is a potential treatment option. The group of participants in the AAAE0544 core study has been taking rhPTH(1-84) for the treatment of hypoparathyroidism for up to 11 years. This st...
What is the current status of trial NCT02910466?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 39 participants. The study started on 2016-10-27. Estimated completion is 2019-12-20.
What conditions does trial NCT02910466 study?
This clinical trial studies the following conditions: Hypoparathyroidism, Chronic Hypoparathyroidism.
What interventions are being tested in trial NCT02910466?
The interventions under investigation include: rhPTH(1-84) (DRUG).
Who is sponsoring clinical trial NCT02910466?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02910466 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypoparathyroidism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Does Treatment of Hypovitaminosis D Increase Calcium Absorption?
COMPLETED · Phase 4
-
A Study to Learn if Recombinant Human Parathyroid Hormone [rhPTH(1-84)] Can Improve Symptoms and Metabolic Control in Adults With Hypoparathyroidism (BALANCE)
COMPLETED · Phase 4
-
A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and Breastfeeding
RECRUITING
-
Hypoparathyroidism Natural History Study
RECRUITING
-
Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)
RECRUITING
-
Parathyroid Allotransplant for Treatment of Hypoparathyroidism
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.